14 results · 21ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

P.004 RC TEMPORARY ABUTMENT, P.004 TEMPORARY HEALING ABUTMENT (CAP)

FDA 510(k)
FDA Class 2 ·Dental

THE CYBERKNIFE SYSTEM FOR STEREOTACTIC RADIOSURGERY/ RADIOTHERAPY V2.1

FDA 510(k)
FDA Class 2 ·Radiology

DIDECO D901 LILLIPUT HOLLOW FIBER OXYGENATOR WITH OR WITHOUT SOFT VENOUS RESERVOIR BAG, WITH BIOCOMPATABLE TREATMENT SUR

FDA 510(k)
FDA Class 2 ·Cardiovascular

NV GXL LINR, NTRL, 32MM ID, GROUP 2 CUPS

FDA Adverse Event
Injury ·EXACTECH, INC.·Product code MEH·July 20, 2022

NV GXL LNR, LIPPED, 36MM ID, GROUP 3 CUPS

FDA Adverse Event
Injury ·EXACTECH, INC.·Product code JDI·July 9, 2024

DEXTRUS 4135

FDA Adverse Event
Injury ·BIOTRONIK SE & CO. KG·Product code NVN·April 22, 2013

IN TOUCH EU

FDA Adverse Event
Malfunction ·STRYKER MEDICAL·Product code FNL·March 29, 2011

CAPTIVATOR II

FDA Adverse Event
Malfunction ·BOSTON SCIENTIFIC·Product code FDI·July 7, 2008

DIDECO D901 LILLIPUT HOLLOW FIBER OXYGENATOR

FDA Adverse Event
Malfunction ·SORIN GROUP ITALIA SRL·Product code DTZ·September 15, 2022

NV GXL LINR, NTRL, 28MM ID, GROUP 1 CUPS

FDA Adverse Event
Injury ·EXACTECH, INC.·Product code JDI·October 11, 2024

DIDECO D901 LILLIPUT HOLLOW FIBER OXYGENATOR

FDA Adverse Event
Malfunction ·SORIN GROUP ITALIA SRL·Product code DTZ·September 14, 2022

NV GXL LINR, NTRL, 36MM ID, GROUP 3 CUPS

FDA Adverse Event
Injury ·EXACTECH, INC.·Product code JDI·October 28, 2024

Aurora 4 Series, Aurora 7 lighthead; Models: AUA7 (including TV models). The Aurora Series is intended to illuminate the surgical field and ensure visibility of the surgical site.

FDA Enforcement
Class II ·Ongoing·DKK Dai-Ichi Shomei Co., Ltd.·August 21, 2024

CADD-Solis VIP ambulatory Infusion Pumps, Model 2120 (21-2120, 21-2125, and 21-2127) Indicated for the following uses: Intra-arterial, subcutaneous, intraperitoneal, in close proximity to nerves, into an intraoperative site, epidural space or subarachnoid space. Therapies that require a continuous rate of infusion, intermittent bolus, and/or with patient-controlled demand doses.

FDA Enforcement
Class I ·Ongoing·Smiths Medical ASD Inc.·August 14, 2024